Table 2.
Univariable and multivariable regression analysis of response and PFS to anti-PD1 treatment
| Best Response (DCR) | ||||
| Parameters | Univariable Logistic Regression | Multivariable Logistic Regression | ||
| HR (95% CI) | p | HR (95% CI) | p | |
| Age* (<69.5 Vs > 69.5 Years) |
2.87 (0.87–9.44) | 0.083 | ||
| Gender (Male Vs Female) |
1.03 (0.31–3.42) | 0.959 | ||
| Braf (Braf wt Vs Braf mt) |
1.27 (0.36–4.41) | 0.702 | ||
| Prior Systemic Therapy (No Vs Yes) | 0.53 (0.16–1.75) | 0.304 | ||
| Tumor Stage (M0, M1a, M1b Vs M1c, M1d) |
0.60 (0.16–2.14) | 0.432 | ||
| Liver Metastases (No Vs Yes) |
1.23 (0.25–5.87) | 0.794 | ||
| Brain Metastses (No Vs Yes) |
1.3 (0.40–4.15) | 0.658 | ||
| LDH (Normal Vs Elevated) |
0.20 (0.05–0.80) | 0.024 | 0.17 (0.03–0.89) | 0.036 |
| Monocytes* (<0.4 Vs > 0.4/nl) |
3.66 (1.07–12.51) | 0.038 | 5.18 (1.14–23.44) | 0.033 |
| sLAG3* (<148 Vs >148 pg/ml) |
0.18 (0.05–0.66) | 0.009 | 0.15 (0.03–0.68) | 0.014 |
| Progression-Free Survival (PFS) | ||||
| Parameters | Univariable Cox Regression | Multivariable Cox Regression | ||
| HR (95% CI) | p | HR (95% CI) | p | |
| Age* (<69.5 Vs > 69.5 Years) |
1.67 (0.79–3.51) | 0.176 | ||
| Gender (Male Vs Female) |
0.85 (0.40–1.82) | 0.691 | ||
| Braf (Braf wt Vs Braf mt) |
1.34 (0.58–3.07) | 0.483 | ||
| Prior Systemic Therapy (No Vs Yes) | 0.65 (0.29–1.41) | 0.275 | ||
| Tumor Stage (M0, M1a, M1b Vs M1c, M1d) |
0.95 (0.43–2.10) | 0.902 | ||
| Liver Metastases (No Vs Yes) |
0.97 (0.37–2.57) | 0.962 | ||
| Brain Metastses (No Vs Yes) |
1.31 (0.62–2.76) | 0.474 | ||
| LDH (Normal Vs Elevated) |
0.41 (0.19–0.90) | 0.026 | 0.41 (0.18–0.91) | 0.030 |
| Monocytes* (<0.4 Vs > 0.4/nl) |
1.72 (0.82–3.59) | 0.148 | ||
| sLAG3* (<148 Vs >148 pg/ml) |
0.40 (0.19–0.85) | 0.018 | 0.39 (0.18–0.84) | 0.016 |
*Age, monocytes, and sLAG3 were dichotomized for regression analysis based on ROC cutoff values with the response as an event